Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
patisiran
6
×
alnylam pharmaceuticals
boston
clinical trials
fda
national top stories
akcea therapeutics
drugs
hereditary transthyretin amyloidosis
inotersen
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
tafamidis
pfizer
biotech
san francisco blog main
san francisco top stories
vyndaqel
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
anylam pharmaceuticals
barry greene
boehringer ingelheim
boston university
cardiomyopathy
craig mello
dan ollendorf
deals
dicerna pharamceuticals
What
alnylam
drug
fda
medicine
ago
pharmaceuticals
rna
rnai
approved
disease
gene
interference
medicines
patients
protein
uses
afternoon
akcea
alnylam’s
amyloidosis
approval
approve
approves
attr
available
awaits
battle
biological
caught
causing
cells
crossed
debilitating
decades
decision
dicerna
discovered
ema
employ
europe
Language
unset
Current search:
patisiran
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision